Akèy › Sendwòm myelodisplastik › North Carolina
Etid klinik pou Sendwòm myelodisplastik nan North Carolina
19 etid pou Sendwòm myelodisplastik ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- ak 5 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT05564390Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Duke University Medical Center, Durham
- East Carolina University, Greenville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Wake Forest University Health Sciences, Winston-Salem
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06484062Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Atrium Health Wake Forest Baptist, Winston-Salem
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health Care Institute, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07422480Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- University of North Carolina at Chapel Hill, Chapel Hill
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06846606Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- ak 4 plis
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health-Cancer Institute, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06499285ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06656494Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Duke Cancer Institute, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT05308264Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Chapel Hill
- Research Site, Durham
Ap rekriteFaz 1/2
Laj 16 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT07155226Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- ak 4 plis
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Duke University, Durham
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Apr 13, 2026 · NCT01890486A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- UNC Hospital, Chapel Hill
- Duke University, Durham
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Duke Cancer Center, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jan 16, 2026 · NCT05143996SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 27, 2025 · NCT01137643Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.